-+ 0.00%
-+ 0.00%
-+ 0.00%

Valbiotis says REVERSE-IT trial results for Totum•63 cut fasting blood glucose, published in Nature Communications

PUBT·07/22/2026 15:44:16
Listen to the news
Valbiotis says REVERSE-IT trial results for Totum•63 cut fasting blood glucose, published in Nature Communications
  • Valbiotis reported Nature Communications publication of REVERSE-IT results for Totum•63 in prediabetes or early type 2 diabetes.
  • Findings were previously presented at the American Diabetes Association 2024 meeting, then highlighted at the European Association for the Study of Diabetes 2024.
  • The placebo-controlled European trial showed improved blood sugar control, meeting the primary goal, with broader cardiometabolic benefits.
  • Safety profile appeared favorable, with no specific safety signal, supporting use as a non-drug nutritional option for early intervention.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valbiotis SA published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.